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ABSTRACT
Background  The efficacy of adjuvant chemotherapy 
in stage II colorectal cancer (CRC) patients has not been 
clearly demonstrated. Therefore, identification of robust 
prognostic factors is crucial for the assessment of recur-




histologically diagnosed stage II CRC.
Results  Receiver operating characteristic  (ROC) 
analysis,  to evaluate  the predictive ability of certain 
serum factors  for CRC  recurrence,  indicated  that  the 






rates of patients with CEAHigh and PNILow, CEAHigh 
and PNIHigh, CEALow and PNILow, and CEALow and 
PNIHigh were 34.3%, 0%, 6.8%, and 2.6%, respectively 
(a significant difference at P < 0.0001). Logistic regres-
sion analysis  revealed  that  the combination of  serum 
CEA level and PNI was an  independent predictive 
indicator of  tumor  recurrence after operation  in  stage 


















value  in prospective clinical  studies.4  In  this context, 
the identification of robust prognostic factors is crucial 
for appropriate assessment of  recurrence  risk  in  stage 











CRC.5–7 However,  it  remains unclear whether  these 
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were excluded  from  this  study. The clinicopathologic 
findings were determined according  to  the  Japanese 
Classification of Colonic Carcinoma.8
Adjuvant chemotherapy was principally performed 




included  in  the current  study, 34 patients underwent 
adjuvant chemotherapy with 5-f luorouracil  (5-FU) 



















vascular  invasion, were obtained  from  the hospital 





19-9 (CA19-9),  and CRP  from patients’ preoperative 
blood  test  results  (within one month before  surgery). 




using  the  formula: 10 × serum albumin  level  (g/dL) + 
0.005 ×  total peripheral LC (/mm3).9 CRP  to albumin 
ratio was defined by dividing  the  serum CRP level 
by  the  serum albumin  level. The controlling nutrition 
status  (CONUT)  score was calculated based on serum 













biomarkers  for  tumor  recurrence. The Youden  index 
was calculated by ROC  analysis  to determine optimal 











Berkeley, CA) software were used  for  the  statistical 
analyses.
RESULTS
Clinicopathological features of the patients includ-









in 12 patients,  the number of  lymph nodes  removed 
in  surgery < 12  in 30 patients,  intestinal occlusion  in 
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Prognostic indicator in stage II CRC
ROC  curves were constructed, and  the AUC values 
were compared  to assess  the ability of  serum-based 
indicators  (Table 2)  to predict CRC  recurrence. The 
AUC of PNI was the highest, followed by serum CEA 
level, indicating that they are most useful in identifying 
high-risk stage II CRC patients,  among  the  indicators 
included  in  this  study. Although  there was a  statisti-
cally  significant correlation between CEA and PNI, 
the  relative coefficient was  low (r = −0.22, P = 0.012, 
Fig. 1). This  indicates  that  the combination of CEA 
and PNI might be more useful than either CEA or PNI 
alone,  in  identifying high-risk  stage  II CRC patients. 
ROC  analysis  indicated  that optimal cutoff values of 
CEA and PNI were 4.55 ng/mL and 47.72, respectively. 
Based on  these cutoff values, patients were divided 
as  follows; CEAHigh  (≥ 4.55 ng/mL), CEALow  (< 4.55 
ng/mL), PNIHigh  (≥ 47.72), and PNILow  (< 47.72). The 
number of patients with CEAHigh and PNILow, CEAHigh 
and PNIHigh, CEALow and PNILow, and CEALow and 
PNIHigh were 35, 17, 44, and 39. The  recurrence  rates 
of patients with CEAHigh and PNILow, CEAHigh and 




nation of serum CEA level and PNI was an independent 














number of patients with CEAHigh and PNILow, CEAHigh 




PNILow, CEAHigh and PNIHigh, CEALow and PNILow, and 
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invasion:  ly0–ly3, grade of  lymphatic  invasion. §Venous  inva-
sion: v0–v3, grade of venous  invasion.  ||Colorectal obstruction 
due  to colorectal cancer based on  the  findings of abdominal 
computed tomography and colonoscopy.
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five-year disease-specific survival rates were 72.9% and 
95.5% in patients with CEAHigh and PNILow and other 
patients,  respectively  (P = 0.0097; Fig. 4c).  In  stage 
II CRC patients without adjuvant chemotherapy,  the 
recurrence rates were 25.9% and 4.1% in patients with 
CEAHigh and PNILow and other patients, respectively (P 
= 0.0033; Fig. 4b). Furthermore,  the five-year disease-
specific survival rates were 78.3% and 100% in patients 
with CEAHigh and PNILow and other patients,  respec-
tively (P < 0.0001; Fig. 4d).
DISCUSSION














in stage II CRC patients. In fact, a recent study failed to 
demonstrate the effectiveness of adjuvant chemotherapy 
Table 2. Receiver operating characteristic analysis of possible recurrence indicators
AUC 95% CI P value
CEA 0.665 0.508–0.823 0.032
CA19-9 0.567 0.387–0.748 0.38
NLR 0.522 0.364–0.680 0.78
PLR 0.616 0.474–0.757 0.13
MLR 0.655 0.514–0.796 0.044
PNI 0.693 0.574–0.812 0.012
CRP / ALB 0.559 0.390–0.727 0.45
CONUT score 0.650 0.524–0.777 0.052
ALB, albumin; AUC, area under curve; CI, confidence interval; MLR, monocyte lymphocyte ratio; NLR, neutrophil lymphocyte ratio; 
PLR, platelet lymphocyte ratio
Fig. 1.  The correlation between serum CEA concentration and PNI.
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that  the combination of CEA and PNI was useful  in 
identifying high-risk stage II CRC patients. CEA, a gly-
coprotein, was the first human cancer-associated antigen 





very  low after birth, or  is undetectable. Some  tumors 
produce this protein and its subsequent elevation in the 
serum of those patients allows it to be used as a tumor 
marker  in clinical  tests. CEA  is  recommended by  the 




and  total LC  to evaluate a patient’s nutritional  status. 
The PNI was originally designed to assess perioperative 
Fig. 2.  Recurrence rates of stage II CRC patients according to serum CEA concentration and PNI.
Table 3. Logistic regression analysis of predictive factors associated with recurrence
Variables P value Odds ratio 95% CI
Age (years) (≥ 75 vs. < 75) 0.42 0.520 0.104–2.590
Gender (male vs. female) 0.17 0.345 0.075–1.590
Location (rectum vs. colon) 0.38 2.030 0.415–9.900
Depth of invasion (T4 vs. T3) 0.64 1.610 0.211–12.30
Approach (laparoscopy vs. open) 0.39 1.970 0.414–9.360
Histology (undifferentiated vs. differentiated) 0.09 5.800 0.749–44.80
Intestinal occlusion (present vs. absent) 0.54 1.840 0.258–13.10
Lymphatic invasion (ly2/3 vs. ly 0/1) 0.87 1.120 0.272–4.640
Vascular invasion (v2/3 vs. v0/1) 0.37 1.830 0.484–6.940
Number of dissected lymph nodes (< 12 vs. ≥ 12) 0.76 0.753 0.125–4.540
Adjuvant chemotherapy (present vs. absent) 0.46 1.740 0.402–7.500
CEA and PNI (CEAHighPNILow vs. others) 0.0005 14.50 3.200–65.80
CI, confidence interval. See table 1 for the detail of depth of invasion and lymphatic or vascular invasion.
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nutritional conditions and postoperative complications 
in patients with CRC in Japan.9 It is simple to calculate 




results  in  its  low serum concentration.14 Therefore, 
the PNI  is  also  influenced by patients’  inflammation 




prognostic  indicator  in CRC patients.7 The close cor-
relation between low PNI and high recurrence rate was 
observed  in  this  study.  In  this  regard, The LC, which 
is  indicator used  to determine  the PNI,  is believed  to 
reflect patients’  immune status. Lymphopenia  is  fre-
quently observed in patients with advanced cancer, and 
several studies have shown that a low preoperative LC 








blood and cancer  tissue  in patients with  some  types 
of cancer.19–21 Therefore,  the peripheral LC might be 






of CEA and PNI measurements was more useful  in 
identifying high-risk  stage  II CRC patients  than either 
CEA or PNI values alone. Furthermore, multivariate 
analysis revealed that the combination of CEA and PNI 
values was an independent predictive indicator of recur-
rence in stage II CRC patients. Notably, the T stage, the 
number of dissected lymph nodes, vascular or lymphatic 
invasion, and  intestinal occlusion, all of which were 
recommended  in most guidelines  to  identify high-risk 
stage II CRC, were not  identified as predictive  indica-
tors  in  this  study. CEA  is principally produced by  the 
tumor cells, whereas PNI reflects the patient’s immune, 
inflammation, and nutritional  states. Our  results  indi-
cate that it is important to consider both cancer-related 
factors and patient-related  factors  in  identifying which 




mellitus. The combination of CEA and PNI is likely to 
minimize  such  influences compared with  the usage of 
CEA alone when predicting the recurrence.
There are  some  limitations with  this  study: As a 
Fig. 3.  Disease-specific survival rates of stage II CRC patients according to serum CEA concentration and PNI.
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sociated with  recurrence  in  stage  II CRC patients.  In 
addition, the number of patients included in the current 
study was small and a  large-scale  trial  is needed  to 
confirm our results.
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